Custom Protein Generation

Drug Substance Manufacturing

Drug Product Fill & Finish




Antibody Drug Conjugates

Technologies & Platforms
Novel Anti-IL-6 Antibody for Rheumatoid Arthritis from WuXi–MedImmune Joint Venture Receives Clinical Trial Permit (CTP) from CFDA (renamed NMPA)
Jan 18, 2017

Milestone represents first-time approval of biologics CTP for a joint multinational-local company venture in China

SHANGHAI and GAITHERSBURG, Md., Jan 18, 2016 — WuXi AppTec Group, a global R&D enabling platform company, and MedImmune, the global biologics research and development arm of AstraZeneca, announced today that an Investigational New Drug (IND) application for WBP216 (MEDI5117), a novel anti-IL-6 antibody for rheumatoid arthritis (RA) and other autoimmune disorders—developed by their joint venture, WuXi MedImmune—has been approved by the China Food and Drug Administration (renamed NMPA) ) as a class I biologic to enter Phase 1 clinical trials in China.

The CFDA’s (renamed NMPA) decision represents the first time that a clinical trial permit (CTP) has been approved for a biologic produced jointly between a multinational corporation and a Chinese company. WuXi has been providing local regulatory, manufacturing, pre-clinical and clinical trial services for the advancement of WBP216.

“We are very pleased that WuXi MedImmune has advanced this important new medicine to a critical milestone,” said Dr. Ge Li, Chairman of WuXi AppTec Group. “WuXi is committed to offering a global enabling platform with the highest quality standards to accelerate the advancement of innovative products to benefit patients in China and around the world.”

“MedImmune and WuXi’s partnership is breaking new ground, not only innovating to potentially address critical patient needs in rheumatoid arthritis, but also leading in the industry as the first multinational-local corporate venture to earn approval of a biologic IND in China,” said Dr. Bahija Jallal, Executive Vice President, MedImmune. “This milestone continues a legacy of firsts that our partnership has established, as our venture was also the first such collaboration in China between a global company and a Chinese company to develop novel biologics. We are pleased to begin the next chapter in our collaboration with WuXi AppTec Group, a company with strong leadership in the Chinese biopharmaceutical sector, with the aim of accelerating Chinese patients’ access to innovative medicines and addressing unmet medical needs around the globe.”

RA is a chronic systemic disease affecting the joints, connective tissues, muscle, tendons, and fibrous tissue, often causing pain and deformity. RA affects approximately 5 million patients in China. Currently, the pathology of RA has not been fully determined in the scientific and medical communities, making the development of effective RA therapies a major challenge in the field of rheumatology.

About WBP216

WBP216 (also known as MEDI5117) is currently being studied in autoimmune and inflammatory diseases such as rheumatoid arthritis. WBP216, a novel investigational biologic, is a fully humanized monoclonal IgG antibody that depletes IL-6 and bears MedImmune’s proprietary half-life extending mutation on its Fc region (known as the “YTE” technology) designed to give a long duration of action. IL-6 is known to be an important mediator in the production of inflammation and pain in a variety of pathologic states.